The Stages of Alzheimer's: How Knowing Them Can Help With Caregiving

While Alzheimer’s disease will progress differently for each person, scientists and clinicians have attempted to stage the disease as a way that helps people living with Alzheimer’s and their families understand what is happening, as well as to plan for the future. Some divide AD into seven stages, some five stages, but currently, three stages is the format most often used. The Alzheimer's Association uses three stages, so that is what we will use for our foundation here. Read the full article on HealthCentral to learn more about the stages of Alzheimer's and how knowing them can help you as a caregiver: Carol is the Candid Caregiver Support a caregiver or jump-start discussion in support groups with real stories - for bulk orders of Minding Our Elders e-mail Carol                  Related StoriesAvoid These 9 Things When Caring for Someone Living With Alzheimer'sIs It Possible to Live with a Positive Outlook Despite Diagnosis?There Are Many Types of Dementia: Alzheimer's Is Only One of Them 
Source: Minding Our Elders - Category: Geriatrics Authors: Source Type: blogs

Related Links:

Conditions:   Mild Cognitive Impairment;   Dementia;   Intermittent Claudication Intervention:   Behavioral: Leg ischemia Sponsors:   Aristotle University Of Thessaloniki;   Greek Alzheimer's Association and Related Disorders Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Publication date: November 2019Source: Alzheimer's &Dementia, Volume 15, Issue 11Author(s):
Source: Alzheimer's and Dementia: The Journal of the Alzheimer's Association - Category: Geriatrics Source Type: research
Publication date: November 2019Source: Alzheimer's &Dementia, Volume 15, Issue 11Author(s):
Source: Alzheimer's and Dementia: The Journal of the Alzheimer's Association - Category: Geriatrics Source Type: research
Publication date: November 2019Source: Alzheimer's &Dementia, Volume 15, Issue 11Author(s): Stacie Weninger, Bjorn Sperling, Lisa J. Bain, Maria C. Carillo
Source: Alzheimer's and Dementia: The Journal of the Alzheimer's Association - Category: Geriatrics Source Type: research
Publication date: November 2019Source: Alzheimer's &Dementia, Volume 15, Issue 11Author(s):
Source: Alzheimer's and Dementia: The Journal of the Alzheimer's Association - Category: Geriatrics Source Type: research
DiscussionThe Cognigram was well liked in waiting rooms of primary care settings. Assistance from a trained adult and clinic endorsement were keys to success. How the Cognigram performs in a geographically compact, population-dense global setting, such as Brooklyn with high vascular disease risk and a plethora of health disparities, is being tested.
Source: Alzheimer's and Dementia: The Journal of the Alzheimer's Association - Category: Geriatrics Source Type: research
Publication date: November 2019Source: Alzheimer's &Dementia, Volume 15, Issue 11Author(s):
Source: Alzheimer's and Dementia: The Journal of the Alzheimer's Association - Category: Geriatrics Source Type: research
Publication date: November 2019Source: Alzheimer's &Dementia, Volume 15, Issue 11Author(s):
Source: Alzheimer's and Dementia: The Journal of the Alzheimer's Association - Category: Geriatrics Source Type: research
Because old age is the greatest risk factor for dementia, a successful therapy will require an understanding of the physiological changes that occur in the brain with aging. Here, two structurally distinct Alzheimer's disease (AD) drug candidates, CMS121 and J147, were used to identify a unique molecular pathway that is shared between the aging brain and AD. CMS121 and J147 reduced cognitive decline as well as metabolic and transcriptional markers of aging in the brain when administered to rapidly aging SAMP8 mice. Both compounds preserved mitochondrial homeostasis by regulating acetyl-coenzyme A (acetyl-CoA) metabolism. C...
Source: eLife - Category: Biomedical Science Tags: Neuroscience Source Type: research
Conclusion: FDG-PET-based visual and cortex ID classification has a good accuracy in predicting progression to dementia including AD in the prodromal aMCI phase. Absence of typical metabolic patterns on FDG-PET can play an important exclusionary role for progression to dementia. Vascular cognitive impairment with cerebral atrophy needs further studies to confirm and uncover potential mechanisms.
Source: Neurology India - Category: Neurology Authors: Source Type: research
More News: Alzheimer's | Dementia | Geriatrics | Learning | Universities & Medical Training